Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting.

Authors :: Fougerousse AC
Maccari F
Beauchet A
Parier J
Boulard C
Becherel PA
Quiles-Tsimaratos N
Le Guyadec T
Thomas-Beaulieu D
Halioua B
Begon E
Bastien M
Perrot JL
Pallure V
Bilan P
Steff M
Pfister P
Vermersch-Langlin A
Boyé T
Mery-Bossard L
Maillard H
Kemula M
Girard C
Poiraud C
Monfort JB
Kupfer-Bessaguet I
Perrussel M
Lons-Danic D
Sultan N
Lorier E
Zeitoun M
Wagner L
Gabison G
Mahé E
Source :: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2019 Dec; Vol. 33 (12), pp. e476-e478. Date of Electronic Publication: 2019 Jul 30.
Publication Year :: 2019

Subjects :: Adult
Aged
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
Thalidomide therapeutic use
Clinical Decision-Making
Dermatologic Agents therapeutic use
Methotrexate therapeutic use
Psoriasis drug therapy
Thalidomide analogs & derivatives

Language :: English
ISSN :: 1468-3083
Volume :: 33
Issue :: 12
Database :: MEDLINE
Journal :: Journal of the European Academy of Dermatology and Venereology : JEADV
Publication Type :: Report
Accession number :: 31310364
Full Text :: https://doi.org/10.1111/jdv.15804

Full Text Access

Tools